HealthLeaders Media February 14, 2019
A deal that might have easily passed antitrust review a decade ago on account of its verticality may face greater skepticism these days from not only the DOJ and FTC but judges as well.
KEY TAKEAWAYS
Some public comments raised vertical concerns about the CVS-Aetna deal, but the DOJ says those possible harms were ‘unlikely to occur.’
The judge’s review of the $69 billion deal comes as some see rising skepticism of vertical mergers.
The case offers a reminder for healthcare executives, especially, to anticipate potential anticompetitive concerns in light of shifting enforcement trends.
The federal government’s review of a megamerger between CVS Health and Aetna is a step closer to final judgment after...
Today's Sponsors
Today's Sponsor